Keywords: drug-eluting balloon; in-stent restenosis; paclitaxel-coated balloon; percutaneous coronary intervention; target lesion failure; BSR; drug-eluting balloon-to-stent ratio; CI; confidence interval; DEB; drug-eluting balloon; DES; drug-eluting stent(s)
مقالات ISI (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: biodegradable polymers; bioresorbable vascular scaffold; bleeding; drug-eluting stent; percutaneous coronary intervention; stent restenosis; stent thrombosis; 1G-DES; first-generation drug-eluting stent(s); 2G-DES; second-generation drug-eluting stent(s);
Keywords: BRS; bioresorbable scaffold; DAPT; dual antiplatelet therapy; MACE; major adverse cardiac event; ST; stent or scaffold thrombosis; TAT; triple antithrombotic therapy; TLF; target lesion failure; TLR; target lesion revascularization; TVF; target vessel fai
Keywords: chronic total occlusion; drug-eluting stent(s); full metal jacket; outcome; CTO; chronic total occlusion; DES; drug-eluting stent(s); FMJ; full metal jacket; MI; myocardial infarction; PCI; percutaneous coronary intervention; TLF; target lesion failure;
Keywords: bioresorbable vascular scaffolds; complex coronary lesions; long coronary lesions; vascular reparative therapy; BMS; bare-metal stent(s); BVS; bioresorbable vascular scaffold(s); CI; confidence interval; DES; drug-eluting stent(s); HR; hazard ratio; MI; m
Keywords: ACS; acute coronary syndrome; BVS; bioresorbable vascular scaffold; DES; drug eluting stent; MACE; major adverse cardiovascular events; MI; myocardial infarction; ST; stent/Scaffold Thrombosis; TLF; target lesion failure; TLR; target lesion revascularizat
5-Year Outcome Following Randomized Treatment of All-Comers With Zotarolimus-Eluting Resolute Integrity and Everolimus-Eluting PROMUS Element Coronary Stents
Keywords: DES; long-term outcome; newer-generation drug-eluting stent(s); PCI; percutaneous coronary intervention; PROMUS Element everolimus-eluting stent(s); Resolute Integrity zotarolimus-eluting stent(s); DES; drug-eluting stent(s); EES; everolimus-eluting stent
Long-term follow-up of BVS from a prospective multicenter registry: Impact of a dedicated implantation technique on clinical outcomes
Keywords: BVS; bioresorbable vascular scaffolds; DAPT; double antiplatelet therapy; DES; drug-eluting stent; IVUS; intravascular ultrasound; MDCT; multiple detector computed tomography; LAD; left anterior descending artery; MI; myocardial infarction; OCT; optical c
First Report of the Resolute Onyx 2.0-mm Zotarolimus-Eluting Stent for the Treatment of Coronary Lesions With Very Small Reference Vessel Diameter
Keywords: drug-eluting stent(s); percutaneous coronary intervention; reference vessel diameter; Resolute Onyx; restenosis; stent(s); zotarolimus; DES; drug-eluting stent(s); MACE; major adverse cardiac event(s); MI; myocardial infarction; PCI; percutaneous coronary
Efficacy and Safety of the Absorb Everolimus-Eluting Bioresorbable Scaffold for Treatment of Patients With Diabetes Mellitus
Keywords: bioresorbable vascular scaffolds; coronary artery disease; diabetes; BVS; bioresorbable vascular scaffold; CL; confidence limit; DES; drug-eluting stent(s); EES; everolimus-eluting stent; MI; myocardial infarction; PCI; percutaneous coronary intervention;
5-Year Safety and Efficacy of Resolute Zotarolimus-Eluting Stent
Keywords: drug-eluting stent; percutaneous coronary intervention; Resolute zotarolimus-eluting stent; stent thrombosis; ARC; Academic Research Consortium; DAPT; dual-antiplatelet therapy; DES; drug-eluting stent(s); MI; myocardial infarction; R-ZES; Resolute zotaro
Everolimus- Versus Novolimus-Eluting Bioresorbable Scaffolds for the Treatment of Coronary Artery Disease
Keywords: bioresorbable scaffold; coronary artery disease; percutaneous coronary intervention; BRS; bioresorbable scaffold(s); DAPT; dual-antiplatelet therapy; DES; drug-eluting metal stent(s); eBRS; everolimus-eluting bioresorbable scaffold(s); MACE; major adverse
Long-Term Safety and Efficacy of Platinum Chromium Everolimus-Eluting Stents in Coronary Artery Disease
Keywords: coronary artery disease; drug-eluting stent(s); percutaneous coronary intervention; stent design; CABG; coronary artery bypass grafting; CI; confidence interval; CoCr-EES; cobalt chromium everolimus-eluting stent(s); HR; hazard ratio; LL; long lesions; MI
The SABRE Trial (Sirolimus Angioplasty Balloon for Coronary In-Stent Restenosis)
Keywords: drug-eluting balloon; extended release; in-stent restenosis; porous angioplasty balloon; sirolimus nanoparticle; BMS; bare-metal stent(s); DES; drug-eluting stent(s); ISR; in-stent restenosis; ITT; intention to treat; LLL; late lumen loss; MACE; major adv
First-in-Human Evaluation of a Novel Polymer-Free Drug-Filled Stent
Keywords: drug-eluting stent(s); drug-filled stent(s); percutaneous coronary intervention; polymer-free stent; BMS; bare-metal stent(s); DAPT; dual antiplatelet therapy; DES; drug-eluting stent(s); DFS; drug-filled stent(s); IVUS; intravascular ultrasound; MI; myoc
The State of the Absorb Bioresorbable Scaffold
Keywords: bioresorbable scaffold; polymer poly-L-lactic acid; scaffold thrombosis; BRS; bioresorbable scaffold; CoCr-EES; cobalt-chromium everolimus-eluting stent(s); DAPT; dual antiplatelet therapy; DES; drug-eluting stent(s); IVUS; intravascular ultrasound; OCT;
3-Year Clinical Outcomes With Everolimus-Eluting Bioresorbable Coronary Scaffolds
Keywords: bioresorbable scaffold; prognosis; randomized trial; stent; BVS; bioresorbable vascular scaffold(s); DES; drug-eluting stent(s); EES; everolimus-eluting stent(s); ID-TLR; ischemia-driven target lesion revascularization; MI; myocardial infarction; PCI; per
Everolimus-Eluting Bioresorbable Scaffolds Versus Everolimus-Eluting Metallic Stents
Keywords: bioresorbable vascular scaffold; everolimus-eluting stents; percutaneous coronary intervention; thrombosis; ARD; absolute risk difference; BVS; bioresorbable vascular scaffold(s); EES; everolimus-eluting stent(s); FDA; Food and Drug Administration; ID-TLR
Effect of Technique on Outcomes Following Bioresorbable Vascular Scaffold Implantation
Keywords: bioresorbable vascular scaffold; prognosis; technique; thrombosis; BVS; bioresorbable vascular scaffold(s); DES; drug-eluting stent(s); ILSD; intraluminal scaffold dismantling; PSP; optimal pre-dilation, vessel and device sizing, and post-dilation; ScT; s
Current Interventions for the Left Main Bifurcation
Keywords: bifurcation; left main; stenting techniques; CABG; coronary artery bypass grafting; DES; drug-eluting stent(s); DK; double kissing; FFR; fractional flow reserve; FKB; final kissing balloon; HRPCI; high-risk percutaneous coronary intervention; IABP; intra-
Comparison of outcomes after treatment of in-stent restenosis using newer generation drug-eluting stents versus drug-eluting balloon: Patient-level pooled analysis of Korean Multicenter in-Stent Restenosis Registry
Keywords: ACS; acute coronary syndrome; ARC; Academic Research Consortium; BD-DES; biodurable polymer coated drug-eluting stent; BR-DES; bioresorbable polymer coated drug eluting stent; BMS; bare metal stent; CVA; cerebrovascular accidents; DEB; drug-eluting balloo
Impact of severe lesion calcification on clinical outcome of patients with stable angina, treated with newer generation permanent polymer-coated drug-eluting stents: A patient-level pooled analysis from TWENTE and DUTCH PEERS (TWENTE II)
Keywords: DES; drug-eluting stent; MACE; major adverse cardiac events; MI; myocardial infarction; PCI; percutaneous coronary intervention; POCE; patient-oriented clinical endpoint; TLF; target lesion failure; TLR; target lesion revascularization; TVF; target vessel
Theoretical and experimental evaluation of multi-band EPI for high-resolution whole brain pCASL Imaging
Keywords: ASL; arterial spin labeling; CBF; cerebral blood flow; EPI; echo planar imaging; FA; flip angle; FAIR; flow-sensitive alternating inversion recovery; FOV; field of view; GRAPPA; generalized autocalibrating partially parallel acquisitions; GRE; gradient re
Role of expression site switching in the development of resistance to human Trypanosome Lytic Factor-1 in Trypanosoma brucei brucei
Keywords: BES; bloodstream expression site; ESAG; expression site associated gene; VSG; variant surface glycoprotein; TLF; Trypanosome Lytic Factor; Hygro; hygromycin; MITat; Molteno institute trypanosome antigen type; HpHbR; haptoglobin hemoglobin receptor; ApoA-1